NCT04688723View on ClinicalTrials.gov

Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI

PHASE4UnknownINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

December 23, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

July 1, 2023

Conditions
Coronary Artery DiseaseMyocardial IschemiaMyocardial InfarctionAtrial Fibrillation
Interventions
DRUG

Dabigatran + Ticagrelor

Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.

DRUG

Dabigatran + clopidogrel

Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.

Trial Locations (1)

6419PC

RECRUITING

Zuyderland MC, Heerlen

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Zuyderland Medisch Centrum

OTHER

NCT04688723 - Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI | Biotech Hunter | Biotech Hunter